Literature DB >> 3346577

Natural killer cell activity as a prognostic parameter in the progression to AIDS.

R Voth, S Rossol, E Gräff, H P Laubenstein, H C Schröder, W E Müller, K H Meyer zum Büschenfelde, G Hess.   

Abstract

Entities:  

Mesh:

Year:  1988        PMID: 3346577     DOI: 10.1093/infdis/157.4.851

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  6 in total

1.  Prevalence of anaemia and immunological markers among ghanaian HAART-naïve HIV-patients and those on HAART.

Authors:  W K B A Owiredu; L Quaye; N Amidu; O Addai-Mensah
Journal:  Afr Health Sci       Date:  2011-03       Impact factor: 0.927

2.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

3.  Evidence for circulating activated cytotoxic T cells in HIV-infected subjects before the onset of opportunistic infections.

Authors:  G Vanham; L Kestens; P Gigase; R Colebunders; M Vandenbruaene; L Brijs; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

4.  Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection.

Authors:  U Ziegner; D Campbell; K Weinhold; I Frank; R Rutstein; S E Starr
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

5.  Cytokine-mediated regulation of monocyte/macrophage cytotoxicity in human immunodeficiency virus-1 infection.

Authors:  S Rossol; G Gianni; R Rossol-Voth; H Gallati; W E Müller; K H Meyer zum Büschenfelde
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

6.  Defective natural immunity: an early manifestation of human immunodeficiency virus infection.

Authors:  H Ullum; P C Gøtzsche; J Victor; E Dickmeiss; P Skinhøj; B K Pedersen
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.